Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

After losing market share in recent years, Nike faces near-term challenges such as the sales momentum among competitors. The Federal Trade Commission sued the drug middlemen that health plans use to ...

For people who pay out of pocket, Lilly recently introduced vials of its drug Zepbound that cost as little as 399 dollars a month. To compete, Novo Nordisk ramped up its rebating -- average Wegovy ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

The 20-year deal with Constellation Energy would kick-start the site of the nation's worst nuclear accident. Top-end German carmakers have joined expensive French handbags among the products hit by ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...